KARYOPHARM THERAPEUTICS INC - NOTE 3.000%10/1

Historical Holders from Q4 2019 to Q3 2025

Type / Class
Debt / NOTE 3.000%10/1
All holders as of 30 Sep 2025
Q3 2025
Total 13F principal, excl. options
23,363,000
Holdings value
$18,818,473
% of all portfolios
0%
Number of holders
5
Number of buys
1
Number of sells
-1
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of KARYOPHARM THERAPEUTICS INC - NOTE 3.000%10/1

Period Principal Value Change Price Investors
2025 Q3 23,363,000 $18,818,473 +$3,641 $0.8168 5
2025 Q2 23,363,000 $17,787,228 $0.7620 5
2025 Q1 23,363,000 $17,777,468 $0.7614 5
2024 Q4 23,363,000 $18,181,290 -$20,439 $0.7782 5
2024 Q3 23,363,000 $17,535,188 +$1,520,000 $0.7700 6
2024 Q2 21,363,000 $13,668,131 -$77,761,376 $0.6458 5
2024 Q1 146,918,494 $90,613,439 -$11,662,000,470 $0.5423 11
2023 Q4 170,334,654 $86,027,205 +$11,407,465 $0.5000 11
2023 Q3 147,861,853 $106,877,272 $0.6206 11
2023 Q2 147,861,853 $112,651,752 -$879,387 $0.6775 11
2023 Q1 176,607,744 $150,781,059 +$159,829 $0.7710 11
2022 Q4 157,006,126 $129,433,751 -$509,924 $0.7589 10
2022 Q3 91,657,126 $83,984,443 -$1,736,501 $0.8081 9
2022 Q2 101,389,000 $78,918,752 -$54,523,098 $0.7300 11
2022 Q1 160,811,700 $146,930,092 +$2,122,310 $0.8386 18
2021 Q4 157,667,200 $141,128,926 -$1,119,797 $0.8172 19
2021 Q3 161,228,700 $131,158,902 -$7,147,490 $0.7526 17
2021 Q2 161,123,000 $161,965,451 -$1,201,655 $1.00 17
2021 Q1 162,120,500 $168,019,191 -$24,429,782 $1.04 14
2020 Q4 179,189,000 $224,437,310 +$2,415,747 $1.26 14
2020 Q3 177,172,000 $212,921,099 -$7,311,826 $1.20 14
2020 Q2 179,672,000 $254,147,406 +$146,260 $1.40 17
2020 Q1 179,520,000 $258,406,915 -$1,646,929 $1.45 15
2019 Q4 180,302,000 $258,383,194 +$258,383,194 $1.43 16